Medication topics
Mesalamine articles covering 5-ASA treatment, safety, access, and ulcerative colitis or broader IBD care decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
2 articles
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
